Health Canada clears Rybelsus for cardiovascular risk reduction
The decision gives adults in Canada with type 2 diabetes and heart disease an oral semaglutide cleared for cardiovascular risk reduction, not just blood sugar control.
Health Canada has approved Rybelsus (semaglutide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or are at high risk for those events. The clearance, issued in January 2026, follows the US approval of the same indication in October 2025 [2].
The indication covers three specific outcomes: cardiovascular death, non-fatal heart attack (myocardial infarction) and non-fatal stroke. Under the US label, Rybelsus is cleared to reduce the risk of these events in adults with type 2 diabetes who are at high risk, in addition to its existing use alongside diet and exercise to improve blood sugar control [2].
Rybelsus is an oral GLP-1 receptor agonist taken once daily in the morning on an empty stomach [2]. It was first approved in the US on September 20, 2019, as the first oral GLP-1 for adults with type 2 diabetes [2]. The US Food and Drug Administration granted the cardiovascular risk reduction indication on October 17, 2025 [2]. The specific trial data behind the Canadian decision has not been reported.
Patients in the US should note a naming change in the oral product line. A second oral semaglutide formulation — 1.5 mg, 4 mg and 9 mg tablets, approved December 9, 2024 — was renamed Ozempic tablets on January 30, 2026, when the FDA approved a labeling update [2]. The earlier 3 mg, 7 mg and 14 mg tablets keep the Rybelsus name. The renaming was a US labeling action [2].
Common adverse reactions reported at rates of 5% or higher include nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation [2]. Warnings and precautions listed for the drug include acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation [2].
For comparison, in adult weight-reduction trials, 73% of patients taking Wegovy reported gastrointestinal adverse reactions versus 47% on placebo, with severe reactions reported in 4.1% versus 0.9% [1]. Wegovy is a different semaglutide product, approved for weight management, and its label says it is not recommended in patients with severe gastroparesis [1]. Rybelsus is not approved for weight loss [2].
The Canadian approval adds to a widening set of cardiovascular indications for semaglutide products. Ozempic injection, first approved in the US in December 2017, also carries a cardiovascular risk reduction use in type 2 diabetes, and Wegovy injection, first approved in June 2021, carries one for adults with obesity or overweight [2]. The global semaglutide market was valued at $34.52 billion in 2025 and is projected to reach $39.37 billion in 2026, with North America holding a 69.09% share in 2025 [1].
Why it matters for patients
For adults in Canada with type 2 diabetes and existing heart disease or high cardiovascular risk, the approval means an oral semaglutide is now cleared for a cardiovascular purpose, not only for blood sugar control [2]. Until now, the cardiovascular risk reduction labeling for semaglutide has been most associated with the injected versions, Ozempic and Wegovy [2]. An oral option matters for people who prefer not to use injections or who have had trouble with them.
The clearance is specific. It applies to adults with type 2 diabetes who have established cardiovascular disease or are at high risk for these events, not to everyone who takes the drug [2]. Rybelsus is a prescription medicine with listed warnings, including pancreatitis, kidney injury and low blood sugar when combined with insulin or insulin secretagogues, and it carries common gastrointestinal side effects [2].
Cost is a separate question from approval. Novo Nordisk announced a significant reduction in US list prices for Wegovy, Ozempic and Rybelsus in February 2026 [1], but whether Canadian public drug plans will cover the new cardiovascular indication has not been reported.
What happens next
Novo Nordisk has said the Ozempic pill will be available in the US in the second quarter of 2026 [2]. Whether Health Canada's clearance is followed by provincial or federal coverage decisions, and when, has not been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.